{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:39:35Z","timestamp":1780461575406,"version":"3.54.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T00:00:00Z","timestamp":1768089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFF1205000"],"award-info":[{"award-number":["2023YFF1205000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chemotherapy-induced nausea and vomiting (CINV) significantly impact the patients\u2019 quality of life. Whether the granisetron transdermal delivery system (GTDS) offers better protection than palonosetron against long-delayed (120-168\u2009hours) CINV after highly or moderately emetogenic chemotherapy (HEC\/MEC) had not been prospectively tested.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multicenter, randomized clinical study was conducted in China. Patients scheduled to receive either HEC or MEC were randomly assigned (1:1) to GTDS or palonosetron, each in combination with a neurokinin-1 receptor antagonist (NK1-RA) and dexamethasone. The primary endpoint was the complete response (CR; no vomiting and no rescue medication) rate during the long-delayed phase (120-168\u2009hours), stratified by HEC and MEC categories, to demonstrate the superiority of GTDS over palonosetron.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 150 patients received either GTDS or palonosetron respectively. We found that the GTDS group demonstrated a significantly higher long-delayed CR rate (97.3%) than the palonosetron group (92%) (P\u2009=\u2009.04). This advantage was driven predominantly by the HEC subgroup (GTDS 97.5% vs palonosetron 90.8%, P\u2009=\u2009.028). No significant differences were observed between the groups for the acute (0-24\u2009hours, 92.7% vs 90.0%; P\u2009=\u2009.412), delayed (24-120\u2009hours, 80.0% vs 76.0%; P\u2009=\u2009.403), extended-delayed (24-168\u2009hours, 80.7% vs 75.3%; P\u2009=\u2009.265), or overall (0-168\u2009hours, 78.0% vs 74.0%; P\u2009=\u2009.417) phases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A GTDS-based triple antiemetic regimen can effectively control CINV associated with HEC or MEC. It provides a convenient alternative route for delivering granisetron for up to 7\u2009days, with superior efficacy in controlling long-delayed CINV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Clinicaltrials.gov Identifier: NCT04912271 (in-house ethic number: YBCSG-21-04)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag007","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:47:54Z","timestamp":1767962874000},"source":"Crossref","is-referenced-by-count":1,"title":["Granisetron transdermal delivery system versus palonosetron in the prevention of long-delayed nausea and vomiting: a phase III randomized trial"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4432-6435","authenticated-orcid":false,"given":"Xiaojun","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center , Shanghai 200032,","place":["China"]},{"name":"Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center , Shanghai 200032,","place":["China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai 200032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchun","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center , Shanghai 200032,","place":["China"]},{"name":"Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center , Shanghai 200032,","place":["China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai 200032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqun","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center , Shanghai 200032,","place":["China"]},{"name":"Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center , Shanghai 200032,","place":["China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai 200032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Mu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center , Shanghai 200032,","place":["China"]},{"name":"Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center , Shanghai 200032,","place":["China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai 200032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[{"name":"Minhang Branch, Fudan University Shanghai Cancer Center , Shanghai 201100,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Changhai Hospital, Naval Military Medical University , Shanghai 200433,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6145-0046","authenticated-orcid":false,"given":"Xiaoxiang","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Nanjing Medical University , Nanjing 210000,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3208-3106","authenticated-orcid":false,"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center , Shanghai 200032,","place":["China"]},{"name":"Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center , Shanghai 200032,","place":["China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai 200032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,11]]},"reference":[{"key":"2026021302361591900_oyag007-B1","doi-asserted-by":"publisher","first-page":"CD012775","DOI":"10.1002\/14651858","article-title":"Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis","volume":"11","author":"Piechotta","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2026021302361591900_oyag007-B2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40265-013-0019-1","article-title":"Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents","volume":"73","author":"Navari","year":"2013","journal-title":"Drugs"},{"key":"2026021302361591900_oyag007-B3","doi-asserted-by":"publisher","first-page":"18745","DOI":"10.1002\/cam4.6494","article-title":"Influence of menopause on chemotherapy-induced nausea and vomiting in highly emetogenic chemotherapy for breast cancer: a retrospective observational study","volume":"12","author":"Yokokawa","year":"2023","journal-title":"Cancer Med"},{"key":"2026021302361591900_oyag007-B4","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026021302361591900_oyag007-B5","doi-asserted-by":"publisher","first-page":"102195","DOI":"10.1016\/j.esmoop.2023.102195","article-title":"2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","volume":"9","author":"Herrstedt","year":"2024","journal-title":"ESMO Open"},{"key":"2026021302361591900_oyag007-B6","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s00520-024-08462-x","article-title":"2020 ASCO, 2023 NCCN, 2023 MASCC\/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients","volume":"32","author":"Kennedy","year":"2024","journal-title":"Support Care Cancer"},{"key":"2026021302361591900_oyag007-B7","doi-asserted-by":"publisher","first-page":"650","DOI":"10.5056\/jnm15203","article-title":"Granisetron transdermal system for treatment of symptoms of gastroparesis: a prescription registry study","volume":"22","author":"Midani","year":"2016","journal-title":"J Neurogastroenterol Motil"},{"key":"2026021302361591900_oyag007-B8","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1007\/s13346-021-00909-6","article-title":"Enhancement strategies for transdermal drug delivery systems: current trends and applications","volume":"12","author":"Ramadon","year":"2022","journal-title":"Drug Deliv Transl Res"},{"key":"2026021302361591900_oyag007-B9","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s00520-015-2865-8","article-title":"Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study","volume":"24","author":"Seol","year":"2016","journal-title":"Support Care Cancer"},{"key":"2026021302361591900_oyag007-B10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.21037\/cco.2017.04.02","article-title":"Granisetron transdermal delivery system is effective in the control of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC) in China","volume":"6","author":"Yang","year":"2017","journal-title":"Chin Clin Oncol"},{"key":"2026021302361591900_oyag007-B11","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3904\/kjim.2020.359","article-title":"Efficacy of the granisetron transdermal system for the control of nausea and vomiting induced by highly emetogenic chemotherapy: a multicenter, randomized, controlled trial","volume":"38","author":"Sun","year":"2023","journal-title":"Korean J Intern Med"},{"key":"2026021302361591900_oyag007-B12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00520-020-05484-z","article-title":"A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation","volume":"29","author":"Armbruster","year":"2021","journal-title":"Support Care Cancer"},{"key":"2026021302361591900_oyag007-B13","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/JCO.21.01315","article-title":"Randomized, double-blind, phase III study of fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting: CONSOLE","volume":"40","author":"Hata","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026021302361591900_oyag007-B14","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40487-022-00188-2","article-title":"Exploratory analysis comparing fosnetupitant versus. fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting (CINV): a randomized, double-blind, phase 3 study (CONSOLE)","volume":"10","author":"Hata","year":"2022","journal-title":"Oncol Ther"},{"key":"2026021302361591900_oyag007-B15","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s10147-015-0786-7","article-title":"Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan","volume":"20","author":"Tamura","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"2026021302361591900_oyag007-B16","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00520-023-07978-y","article-title":"Prevalence and predictors of long- delayed (&gt; 120 h) chemotherapy-induced nausea and vomiting (CINV)-a systematic review and individual patient data meta- analysis","volume":"31","author":"Chow","year":"2023","journal-title":"Support Care Cancer"},{"key":"2026021302361591900_oyag007-B17","doi-asserted-by":"publisher","first-page":"e1870","DOI":"10.1002\/onco.13888","article-title":"A pragmatic study evaluating NEPA versus aprepitant for prevention of chemo- therapy-induced nausea and vomiting in patients receiving moder- ately emetogenic chemotherapy","volume":"26","author":"Zelek","year":"2021","journal-title":"Oncologist"},{"key":"2026021302361591900_oyag007-B18","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s12185-016-2152-6","article-title":"Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: a phase II study","volume":"105","author":"Isoda","year":"2017","journal-title":"Int J Hematol"},{"key":"2026021302361591900_oyag007-B19","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00520-010-0893-y","article-title":"Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study","volume":"19","author":"Rozzi","year":"2011","journal-title":"Support Care Cancer"},{"key":"2026021302361591900_oyag007-B20","author":"National Comprehensive Cancer Network (NCCN)","year":"2023"},{"key":"2026021302361591900_oyag007-B21","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw217","article-title":"Neurokinin-1 receptor antagonist-based triple regimens in preventing chemotherapy-induced nausea and vomiting: a network meta-analysis","volume":"109","author":"Zhang","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"2026021302361591900_oyag007-B22","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/jnci\/djw217","article-title":"Palonosetron for the prevention of chemotherapy-induced nausea and vomiting","volume":"13","author":"Mori-Vogt","year":"2013","journal-title":"Expert Rev Anticancer Ther"},{"key":"2026021302361591900_oyag007-B23","doi-asserted-by":"publisher","first-page":"18095","DOI":"10.1038\/s41598-025-01632-9","article-title":"Efficacy of olanzapine as an antiemetic drug for transcatheter arterial chemoembolization for hepatocellular carcinoma","volume":"15","author":"Oura","year":"2025","journal-title":"Sci Rep"},{"key":"2026021302361591900_oyag007-B24","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1080\/14656566.2023.2288288","article-title":"Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy","volume":"24","author":"Hayashi","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"2026021302361591900_oyag007-B25","doi-asserted-by":"publisher","first-page":"4928","DOI":"10.1007\/s12325-023-02648-1","article-title":"Pooled analysis of studies evaluating fosnetupitant and risk factors for cisplatin-induced nausea and vomiting during the extended overall phase","volume":"40","author":"Inui","year":"2023","journal-title":"Adv Ther"},{"key":"2026021302361591900_oyag007-B26","doi-asserted-by":"publisher","first-page":"93.e1-4","DOI":"10.1016\/j.ajog.2016.01.163","article-title":"Pharmacodynamics of transdermal granisetron in women with nausea and vomiting of pregnancy","volume":"215","author":"Caritis","year":"2016","journal-title":"Am J Obstet Gynecol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag007\/66341864\/oyag007.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/3\/oyag007\/66341864\/oyag007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/3\/oyag007\/66341864\/oyag007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:36:22Z","timestamp":1770968182000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag007\/8419903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,11]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag007","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,1,11]]},"article-number":"oyag007"}}